Na Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Na Wang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jinping Zhang
Soochow University
2 shared publications - Wenying Yang
China-Japan Friendship Hospital, Beijing, China
2 shared publications - Xiao-Yan Xing
Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China
2 shared publications - Zhao-Jun Yang
Department of Endocrinology, China-Japan Friendship Hospital, Beijing, People’s Republic of China
2 shared publications - Bo Zhang
Department of Endocrinology China‐Japan Friendship Hospital Beijing China
1 shared publication Jie Li
The 4th Department of Psychiatry, Jining Psychiatric Hospital, Jining 272000, People's Republic of China
1 shared publication
Latest Publications
- Retracted
- 6 September 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 121 (2) , 984-995
RETRACTED: miR‐125a‐3p suppresses the growth and progression of papillary thyroid carcinoma cell by targeting MMP11
The dysregulation of miR‐125a‐3p has been observed in multiple tumor types. Nevertheless, the function of miR‐125a‐3p in papillary thyroid carcinoma (PTC) is yet to be explored. Herein, we find that miR‐125a‐3p is markedly downregulated in PTC tissues, and its level is inversely related to the histological grade of PTC. Upregulation of miR‐125a‐3p suppresses the pulmonary metastatic ability as well as the tumor growth of PTC cell in vivo. Consistently, the colony formation ability and other metastasis‐related traits of PTC cell are inhibited by miR‐125a‐3p transfection in vitro. In addition, we identify that matrix metalloprotease 11 (MMP11) is the direct target gene of miR‐125a‐3p, and that miR‐125a‐3p inhibits cell viability, migration, and invasiveness of PTC cell by reducing MMP11 expression in vitro. Together, these data testify that the miR‐125a‐3p/MMP11 axis plays vital roles in the growth and progression of human PTC cells.
- 6 September 2019
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 121 (2) , 984-995
RetractedRETRACTED: miR‐125a‐3p suppresses the growth and progression of papillary thyroid carcinoma cell by targeting MMP11
The dysregulation of miR‐125a‐3p has been observed in multiple tumor types. Nevertheless, the function of miR‐125a‐3p in papillary thyroid carcinoma (PTC) is yet to be explored. Herein, we find that miR‐125a‐3p is markedly downregulated in PTC tissues, and its level is inversely related to the histological grade of PTC. Upregulation of miR‐125a‐3p suppresses the pulmonary metastatic ability as well as the tumor growth of PTC cell in vivo. Consistently, the colony formation ability and other metastasis‐related traits of PTC cell are inhibited by miR‐125a‐3p transfection in vitro. In addition, we identify that matrix metalloprotease 11 (MMP11) is the direct target gene of miR‐125a‐3p, and that miR‐125a‐3p inhibits cell viability, migration, and invasiveness of PTC cell by reducing MMP11 expression in vitro. Together, these data testify that the miR‐125a‐3p/MMP11 axis plays vital roles in the growth and progression of human PTC cells.
- Open Access
- 1 August 2019
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 12, 1513-1526
Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Purpose: Addition of the dipeptidyl peptidase-4 (DPP4) inhibitors to insulin in patients with type 2 diabetes mellitus (T2DM) may achieve better glycemic control. However, results of pilot randomized controlled trials (RCTs) are inconsistent. We aimed to perform a meta-analysis of RCTs to evaluate efficacy and safety of DPP4 inhibitors compared with placebo/no treatment as add-on therapy to insulin in T2DM patients. Materials and methods: Relevant studies were identified via a search of PubMed, Cochrane Library, and Embase databases. A fixed or random effect model was applied according to the heterogeneity. Results: Overall, 22 RCTs with 6,957 T2DM patients were included. Addition of DPP4 inhibitors to insulin was associated with significantly reduced HbA1c as compared with controls (weighed mean difference [WMD]: −0.54%, ppppp=0.81) or risk of symptomatic hypoglycemia (risk ratio: 0.92, p=0.37) were not affected. Conclusions: Addition of DPP4 inhibitors to insulin significantly improved the glycemic control in T2DM patients without further increasing the risk of weight gain and hypoglycemia.
- 1 August 2019
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 12, 1513-1526
Open AccessDipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Purpose: Addition of the dipeptidyl peptidase-4 (DPP4) inhibitors to insulin in patients with type 2 diabetes mellitus (T2DM) may achieve better glycemic control. However, results of pilot randomized controlled trials (RCTs) are inconsistent. We aimed to perform a meta-analysis of RCTs to evaluate efficacy and safety of DPP4 inhibitors compared with placebo/no treatment as add-on therapy to insulin in T2DM patients. Materials and methods: Relevant studies were identified via a search of PubMed, Cochrane Library, and Embase databases. A fixed or random effect model was applied according to the heterogeneity. Results: Overall, 22 RCTs with 6,957 T2DM patients were included. Addition of DPP4 inhibitors to insulin was associated with significantly reduced HbA1c as compared with controls (weighed mean difference [WMD]: −0.54%, ppppp=0.81) or risk of symptomatic hypoglycemia (risk ratio: 0.92, p=0.37) were not affected. Conclusions: Addition of DPP4 inhibitors to insulin significantly improved the glycemic control in T2DM patients without further increasing the risk of weight gain and hypoglycemia.
- Open Access
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 15 (2) , 309-320
MARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
Introduction In this secondary analysis of the Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment (MARCH) trial, we evaluated what demographic and clinical factors were associated with reduction in weight. We also assessed the effects of acarbose and metformin treatment on...
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 15 (2) , 309-320
Open AccessMARCH: factors associated with weight loss in patients with newly diagnosed type 2 diabetes treated with acarbose or metformin
Introduction In this secondary analysis of the Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment (MARCH) trial, we evaluated what demographic and clinical factors were associated with reduction in weight. We also assessed the effects of acarbose and metformin treatment on...
- Open Access
- 4 November 2015
- Published by Wiley in Journal of Diabetes
- Vol. 8 (4) , 559-567
Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels
The aim of the present study was to investigate whether the therapeutic efficacy of acarbose and metformin is correlated with baseline HbA1c levels in Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM). Data for 711 subjects were retrieved from the MARCH (Metformin and AcaRbose in Chinese as initial Hypoglycemic treatment) trial database and reviewed retrospectively. Patients were grouped according to baseline HbA1c levels (8%) and the results for these three groups were compared between acarbose and metformin treatments. Acarbose and metformin treatment significantly improved T2DM-associated parameters (weight, fasting plasma glucose [FPG], postprandial glucose [PPG], glucagon-like peptide-1 [GLP-1], HOMA-IR, and total cholesterol) across all HbA1c levels. Acarbose decreased PPG and HOMA-β significantly more than metformin, but only in subjects with lower baseline HbA1c (PPG in the <7% and 7%-8%, HOMA-β in the <7% groups; all P < 0.05). Acarbose decreased triglyceride (TG) levels, and the areas under the curve (AUC) for insulin and glucagon more than metformin at all HbA1c levels (P < 0.05). After 24 weeks treatment, metformin decreased FPG levels significantly more than acarbose for all baseline HbA1c groups (all P < 0.001). With the exception of FPG, PPG, and TG levels, differences between the two treatment groups observed at 24 weeks were not detected at 48 weeks. Acarbose decreased PPG and TG and spared the AUC for insulin more effectively in patients with low-to-moderate baseline HbA1c levels, whereas metformin induced greater reductions in FPG. These results may help guide selection of initial therapy based on baseline HbA1c.
- 4 November 2015
- Published by Wiley in Journal of Diabetes
- Vol. 8 (4) , 559-567
Open AccessEfficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels
The aim of the present study was to investigate whether the therapeutic efficacy of acarbose and metformin is correlated with baseline HbA1c levels in Chinese patients with newly diagnosed type 2 diabetes mellitus (T2DM). Data for 711 subjects were retrieved from the MARCH (Metformin and AcaRbose in Chinese as initial Hypoglycemic treatment) trial database and reviewed retrospectively. Patients were grouped according to baseline HbA1c levels (8%) and the results for these three groups were compared between acarbose and metformin treatments. Acarbose and metformin treatment significantly improved T2DM-associated parameters (weight, fasting plasma glucose [FPG], postprandial glucose [PPG], glucagon-like peptide-1 [GLP-1], HOMA-IR, and total cholesterol) across all HbA1c levels. Acarbose decreased PPG and HOMA-β significantly more than metformin, but only in subjects with lower baseline HbA1c (PPG in the <7% and 7%-8%, HOMA-β in the <7% groups; all P < 0.05). Acarbose decreased triglyceride (TG) levels, and the areas under the curve (AUC) for insulin and glucagon more than metformin at all HbA1c levels (P < 0.05). After 24 weeks treatment, metformin decreased FPG levels significantly more than acarbose for all baseline HbA1c groups (all P < 0.001). With the exception of FPG, PPG, and TG levels, differences between the two treatment groups observed at 24 weeks were not detected at 48 weeks. Acarbose decreased PPG and TG and spared the AUC for insulin more effectively in patients with low-to-moderate baseline HbA1c levels, whereas metformin induced greater reductions in FPG. These results may help guide selection of initial therapy based on baseline HbA1c.